|
22 Apr 2021 |
Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax's CpG 1018™ Adjuvant
|
|
22 Apr 2021 |
Sirnaomics' Spin-Off RNAimmune Secures $10 Million Seed Financing to Advance its mRNA-Based Vaccine and Therapeutic Development
|
|
18 Apr 2021 |
Aegis Life Announces Start of Phase 1/2 Trial of the Entos COVID-19 DNA Vaccine, Covigenix VAX-001, with First Participants Dosed
|
|
15 Apr 2021 |
INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern
|
|
13 Apr 2021 |
Intravacc announces positive preclinical data for its OMV-based Lyme vaccine
|
|
13 Apr 2021 |
Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA™ COVID-19 Vaccine Candidate in Felines
|
|
12 Apr 2021 |
Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine
|
|
12 Apr 2021 |
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
|
|
11 Apr 2021 |
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers
|
|
11 Apr 2021 |
Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
|
|
07 Apr 2021 |
ERC-USA Announces FDA Recommendation for Early Termination of Phase 2 Clinical Trial of ERC1671 (Gliovac or Sitoiganap) and Application for Registration Trial for Treatment of Glioblastoma
|
|
07 Apr 2021 |
Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials
|
|
07 Apr 2021 |
Intravacc announces positive preclinical data for its SARS-CoV-2 nose spray vaccine
|
|
06 Apr 2021 |
Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
|
|
06 Apr 2021 |
Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover
|
|
02 Apr 2021 |
OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine
|
|
02 Apr 2021 |
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
|
|
31 Mar 2021 |
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
|
|
30 Mar 2021 |
Curevo Vaccine Announces the Approval to Conduct a Phase 1b Clinical Trial in South Africa to Evaluate Safety and Immunogenicity of Its Adjuvanted Subunit Investigational Vaccine, CRV-101, Against Varicella (Chickenpox) in HIV-Positive Children
|
|
29 Mar 2021 |
Gritstone Announces First Person Dosed with its Second-Generation COVID-19 Vaccine in Phase 1 Study Conducted and Supported by NIAID/IDCRC
|
|
27 Mar 2021 |
Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer
|
|
27 Mar 2021 |
University of Oxford to study nasal administration of COVID-19 vaccine
|
|
26 Mar 2021 |
Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
|
|
25 Mar 2021 |
KM Biologics Announces Phase I Clinical Study Results of a Live Attenuated Tetravalent Dengue Vaccine (KD-382)
|
|
25 Mar 2021 |
AZD1222 US Phase III primary analysis confirms safety and efficacy
|
